These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38065240)

  • 1. Uncertain benefit of statins in pediatric heart transplant recipients: A PHTS analysis.
    Townsend M; Khoury M; Koehl D; Kirklin JK; Cantor R; Beasley G; Chen CY; Boyle G; Parent JJ; Baez Hernandez N; Halnon N
    J Heart Lung Transplant; 2024 May; 43(5):703-713. PubMed ID: 38065240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents.
    Greenway SC; Butts R; Naftel DC; Pruitt E; Kirklin JK; Larsen I; Urschel S; Knecht K; Law Y
    J Heart Lung Transplant; 2016 Apr; 35(4):457-65. PubMed ID: 26746989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis.
    D'Addese L; Cantor RS; Koehl D; Reardon L; Ameduri R; Bock M; Morrison A; White S; Wisotzkey B; Kirklin JK; Godown J
    J Heart Lung Transplant; 2023 Jan; 42(1):115-123. PubMed ID: 36328858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation.
    Mahle WT; Vincent RN; Berg AM; Kanter KR
    J Heart Lung Transplant; 2005 Jan; 24(1):63-6. PubMed ID: 15653381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis?
    Khoury M; Conway J; Gossett JG; Edens E; Soto S; Cantor R; Koehl D; Barnes A; Exil V; Glass L; Kirklin JK; Zuckerman WA
    J Heart Lung Transplant; 2022 May; 41(5):578-588. PubMed ID: 35172937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance steroid use at 30 days post-transplant and outcomes of pediatric heart transplantation: A propensity matched analysis of the Pediatric Heart Transplant Study database.
    Auerbach SR; Kukreja M; Gilbert D; Bastardi H; Feingold B; Knecht K; Kaufman BD; Brown RN; Miyamoto SD
    J Heart Lung Transplant; 2015 Aug; 34(8):1066-72. PubMed ID: 25980572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac allograft vasculopathy and graft failure in pediatric heart transplant recipients after rejection with severe hemodynamic compromise.
    Kleinmahon JA; Gralla J; Kirk R; Auerbach SR; Henderson HT; Wallis GA; Ramakrishnan K; Singh RK; Caldwell RL; Savage AJ; Everitt MD
    J Heart Lung Transplant; 2019 Mar; 38(3):277-284. PubMed ID: 30638837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients.
    Kobayashi D; Du W; L'ecuyer TJ
    Pediatr Transplant; 2013 Aug; 17(5):436-40. PubMed ID: 23714284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
    Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and dyslipidemia predict cardiac allograft vasculopathy and graft loss in children and adolescents post-heart transplant: A PHTS multi-institutional analysis.
    Bogle C; Cantor R; Koehl D; Lochridge J; Kirklin JK; Barnes A; Wallis G; Amdani S; Ameduri R; Pahl E; Simpson KE; Blume ED
    Pediatr Transplant; 2022 Aug; 26(5):e14244. PubMed ID: 35122464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up.
    Stojanovic I; Vrtovec B; Radovancevic B; Radovancevic R; Yazdanbakhsh AP; Thomas CD; Frazier OH
    J Heart Lung Transplant; 2005 Sep; 24(9):1235-8. PubMed ID: 16143239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of high-intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus.
    Heeney SA; Tjugum SL; Corkish ME; Hollis IB
    Clin Transplant; 2019 Jan; 33(1):e13454. PubMed ID: 30485535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cardiac allograft vasculopathy incidence between simultaneous multiorgan and isolated heart transplant recipients in the United States.
    Shahandeh N; Kim JS; Klomhaus AM; Tehrani DM; Hsu JJ; Nsair A; Khush KK; Fearon WF; Parikh RV
    J Heart Lung Transplant; 2024 Oct; 43(10):1737-1746. PubMed ID: 38950666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric recipient survival beyond 15 post-heart transplant years: a single-center experience.
    Copeland H; Razzouk A; Chinnock R; Deming D; Hasaniya N; Bailey L
    Ann Thorac Surg; 2014 Dec; 98(6):2145-50; discussion 2150-1. PubMed ID: 25443019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival.
    Younas N; Wu CM; Shapiro R; McCauley J; Johnston J; Tan H; Basu A; Schaefer H; Smetanka C; Winkelmayer WC; Unruh M
    BMC Nephrol; 2010 Apr; 11():5. PubMed ID: 20359353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Statin Use After Heart Transplantation: A Meta-Analysis.
    Vallakati A; Reddy S; Dunlap ME; Taylor DO
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27729391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification to determine the impact of induction therapy on survival, rejection and adverse events after pediatric heart transplant: A multi-institutional study.
    Castleberry C; Pruitt E; Ameduri R; Schowengerdt K; Edens E; Hagin N; Kirklin JK; Naftel D; Urschel S
    J Heart Lung Transplant; 2018 Apr; 37(4):458-466. PubMed ID: 28619384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients.
    Hognestad A; Endresen K; Wergeland R; Stokke O; Geiran O; Holm T; Simonsen S; Kjekshus JK; Andreassen AK
    J Am Coll Cardiol; 2003 Aug; 42(3):477-82. PubMed ID: 12906976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed occurrence of cardiac allograft vasculopathy in Chinese heart transplant recipients compared with their western counterparts.
    Wang HJ; Ko WJ; Leea CM; Hsu RB; Chou NK; Wang SS; Liau CS; Chu SH; Lee YT
    Clin Transplant; 2004 Feb; 18(1):21-7. PubMed ID: 15108767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.